Free Trial
→ The Iran War Just Broke the Gold Market (From Behind the Markets) (Ad)tc pixel Free FSDC Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

FS Development (FSDC) Competitors

FS Development logo
Compare

FSDC vs. GMTX, MOR, ZYME, MBX, and CALT

Should you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Gemini Therapeutics (GMTX), MorphoSys (MOR), Zymeworks (ZYME), MBX Biosciences (MBX), and Calliditas Therapeutics AB (publ) (CALT).

How does FS Development compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and FS Development (NASDAQ:FSDC) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/A-$71.87M-$1.00N/A
FS DevelopmentN/AN/AN/AN/AN/A

In the previous week, Gemini Therapeutics had 1 more articles in the media than FS Development. MarketBeat recorded 1 mentions for Gemini Therapeutics and 0 mentions for FS Development. Gemini Therapeutics' average media sentiment score of 0.00 equaled FS Development'saverage media sentiment score.

Company Overall Sentiment
Gemini Therapeutics Neutral
FS Development Neutral

FS Development's return on equity of 0.00% beat Gemini Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gemini TherapeuticsN/A -38.78% -35.88%
FS Development N/A N/A N/A

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 89.8% of FS Development shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

FS Development beats Gemini Therapeutics on 3 of the 5 factors compared between the two stocks.

How does FS Development compare to MorphoSys?

FS Development (NASDAQ:FSDC) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

89.8% of FS Development shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, FS Development's average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score.

Company Overall Sentiment
FS Development Neutral
MorphoSys Neutral

FS Development has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. FS Development's return on equity of 0.00% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
FS DevelopmentN/A N/A N/A
MorphoSys -226.79%-694.31%-22.55%

FS Development has higher earnings, but lower revenue than MorphoSys.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FS DevelopmentN/AN/AN/AN/AN/A
MorphoSys$238.28M11.99-$205.35M-$3.48N/A

Summary

FS Development beats MorphoSys on 4 of the 6 factors compared between the two stocks.

How does FS Development compare to Zymeworks?

FS Development (NASDAQ:FSDC) and Zymeworks (NASDAQ:ZYME) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

FS Development has a net margin of 0.00% compared to Zymeworks' net margin of -76.56%. FS Development's return on equity of 0.00% beat Zymeworks' return on equity.

Company Net Margins Return on Equity Return on Assets
FS DevelopmentN/A N/A N/A
Zymeworks -76.56%-26.00%-20.57%

FS Development has higher earnings, but lower revenue than Zymeworks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FS DevelopmentN/AN/AN/AN/AN/A
Zymeworks$105.96M18.57-$81.13M-$1.08N/A

Zymeworks has a consensus target price of $37.89, suggesting a potential upside of 42.01%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts clearly believe Zymeworks is more favorable than FS Development.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FS Development
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Zymeworks
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.92

In the previous week, Zymeworks had 3 more articles in the media than FS Development. MarketBeat recorded 3 mentions for Zymeworks and 0 mentions for FS Development. Zymeworks' average media sentiment score of 0.45 beat FS Development's score of 0.00 indicating that Zymeworks is being referred to more favorably in the news media.

Company Overall Sentiment
FS Development Neutral
Zymeworks Neutral

89.8% of FS Development shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Zymeworks beats FS Development on 9 of the 12 factors compared between the two stocks.

How does FS Development compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and FS Development (NASDAQ:FSDC) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

FS Development's return on equity of 0.00% beat MBX Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
MBX BiosciencesN/A -28.72% -27.55%
FS Development N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MBX BiosciencesN/AN/A-$86.97M-$2.41N/A
FS DevelopmentN/AN/AN/AN/AN/A

MBX Biosciences currently has a consensus target price of $53.25, suggesting a potential upside of 79.90%. Given MBX Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe MBX Biosciences is more favorable than FS Development.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.75
FS Development
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, MBX Biosciences' average media sentiment score of 0.00 equaled FS Development'saverage media sentiment score.

Company Overall Sentiment
MBX Biosciences Neutral
FS Development Neutral

89.8% of FS Development shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

MBX Biosciences beats FS Development on 4 of the 7 factors compared between the two stocks.

How does FS Development compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and FS Development (NASDAQ:FSDC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

FS Development has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. FS Development's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96%
FS Development N/A N/A N/A

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 89.8% of FS Development shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

FS Development has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ).

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A
FS DevelopmentN/AN/AN/AN/AN/A

In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled FS Development'saverage media sentiment score.

Company Overall Sentiment
Calliditas Therapeutics AB (publ) Neutral
FS Development Neutral

Summary

FS Development beats Calliditas Therapeutics AB (publ) on 4 of the 6 factors compared between the two stocks.

Get FS Development News Delivered to You Automatically

Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FSDC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FSDC vs. The Competition

Export
MetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$836.70M$883.41M$6.25B$11.76B
Dividend YieldN/A4.84%2.74%5.26%
P/E RatioN/A1.7129.2527.07
Price / SalesN/A119.23504.6973.43
Price / CashN/A20.0743.3053.90
Price / BookN/A7.609.676.69
Net IncomeN/A-$4.80M$3.55B$332.64M

FS Development Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FSDC
FS Development
N/A$66.85
+1.6%		N/A+35.0%$836.70MN/AN/AN/A
GMTX
Gemini Therapeutics
N/A$68.85
+0.8%		N/A+36.6%$2.98BN/AN/A30
MOR
MorphoSys
N/A$18.96
flat		N/AN/A$2.86B$238.28MN/A730
ZYME
Zymeworks
2.475 of 5 stars		$28.56
+1.6%		$37.89
+32.7%		N/A$2.07B$105.96MN/A460
MBX
MBX Biosciences
2.3621 of 5 stars		$31.97
+0.0%		$53.25
+66.6%		N/A$1.52BN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:FSDC) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Did you miss The Dark AI Summit?
Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...
Brownstone Research | Sponsoredtc pixel
Why Elon just bought a power plant (Ticker inside)
Elon Musk is burning nearly $1 billion a month because he cannot power the world's largest supercomputer witho...
Behind the Markets | Sponsoredtc pixel
Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next
Jim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...
Paradigm Press | Sponsoredtc pixel